Back to Evidence

Auditing Endoscopy Plus Quadruple Therapy Research in H. pylori-Associated Gastric Ulcer | QSevidence 2026

Evidence-Based Medicine19 min read

Evaluating endoscopy plus quadruple therapy starts with defining the additional procedure, before judging eradication or healing rates.

Auditing Endoscopy Plus Quadruple Therapy Research in H. pylori-Associated Gastric Ulcer | QSevidence 2026

This Medical intelligence platform perspective from QSevidence connects source tracing, endpoint definitions and statistical review so that each criticism can be checked against evidence.

Investigate questions without presuming misconduct or error

Statistical discussion of combined endoscopic and drug treatment for Helicobacter pylori-associated gastric ulcer concerns baseline summaries, test selection, confidence intervals and multiplicity. Without verified bibliographic details, full tables and analysis data, suspected problems cannot become established errors. A complete original report with a confirmed identity was not obtained for this review. The article therefore offers an audit framework, not an error list or reanalysis verdict about a specific paper.

Begin with the title, authors, journal, year, persistent link, correction or retraction status and document version. Similar titles do not establish identical studies. Every review comment needs an original location, a stated criterion and a record of information still required.

Endoscopic assessment is not automatically an eradication intervention

Endoscopy can document an ulcer, obtain pathology and manage selected complications. Having undergone endoscopy does not automatically constitute an independent anti-H. pylori treatment. Diagnostic inspection, biopsy, hemostasis and other therapeutic procedures have different purposes. A claim of additional benefit requires a precise account of what differs between groups, including timing, indications, operators and subsequent care.

A biopsy intended to exclude malignancy or treatment for bleeding should not be presented as evidence that routine infection eradication improves. If the combined-treatment group includes more bleeding or larger ulcers, indication and severity may influence outcomes. Modeling cannot repair a fundamentally undefined intervention.

The official highlights of the 2024 ACG guideline recommend confirming eradication at least four weeks after therapy. To reduce false-negative tests, PPIs are held for two weeks and antibiotics and bismuth for four weeks before testing. These US recommendations provide endpoint context; individual medication arrangements require clinical supervision and are not instructions to stop treatment independently.

Identify the design before auditing baseline comparisons

A randomized study requires examination of sequence generation, allocation concealment, implementation and deviations. A nonrandomized comparison needs an explanation of how treatment selection relates to prognosis. Relevant baseline information may include age, ulcer size and location, previous eradication treatment, factors affecting adherence and susceptibility information where actually measured. Reviewers must not assume that unreported variables were collected.

The CONSORT 2025 explanation discourages baseline significance tests in randomized trials. An age comparison with P greater than 0.05 does not prove successful randomization or absence of bias; omission of baseline P values is not automatically an error. Focus on the magnitude and prognostic relevance of differences and the prespecified adjustment strategy, rather than selecting covariates because their baseline P values cross a threshold.

Connect the eradication numerator, denominator and time window

Eradication, ulcer healing, symptom improvement and recurrence are separate outcomes. Less pain does not confirm eradication, and a smaller ulcer alone does not prove clearance of infection. Testing methods and timing must be comparable between groups, with relevant recent medication exposure recorded.

Reconstruct numbers enrolled or randomized, treated, retested and confirmed eradicated in each group. Analysis according to randomized assignment and analysis restricted to adherent participants with complete records need not address the same question. Removing everyone without a follow-up test from the denominator must not silently become an estimate for the whole enrolled population.

For binary outcomes, inspect the contingency table, observational unit and independence before evaluating a chi-square test, exact procedure or regression model. Sparse events deserve attention, but total sample size alone does not establish that a test was wrong. Report absolute differences, relative effects and uncertainty rather than declaring superiority from separate percentages.

Do not replace one mechanical test-selection rule with another

Reporting age or a symptom score as a mean and standard deviation is not necessarily incorrect because a normality test was unreported. The estimand, sample size, outliers, variance structure and model residuals matter. Welch methods differ from equal-variance t tests. Automatically switching every analysis according to a Shapiro-Wilk threshold does not ensure validity.

Similarly, a Mann-Whitney test is not generally a test of a median difference without additional distributional assumptions. Scores with few ordered categories need attention to their measurement properties. Repeated assessments require handling within-person correlation. Finding a before-after difference separately in both groups does not establish a difference between treatment effects. Depending on the prespecified question, baseline-adjusted analysis or a longitudinal model may be appropriate, with the choice explained.

P values, uncertainty and safety answer different questions

The American Statistical Association's statement summary explains that a P value is neither the probability that a hypothesis is true nor a measure of effect size or clinical importance. P greater than 0.05 does not establish equivalence. Equivalence or noninferiority claims require the corresponding design, margins and interval interpretation.

Multiple outcomes, time points and subgroups require a defined confirmatory question and testing family, with multiplicity handling explained or findings identified as exploratory. Not every collection of P values requires the same correction. Changing thresholds after seeing results is not a substitute for planning. Without the actual tables, the direction of any bias also remains undetermined.

Safety summaries should distinguish affected people from event counts, and record drug-related and procedure-related events, severity and observation duration. No observed events in either group may indicate limited information rather than zero risk. Sparse safety findings may call for transparent descriptions and intervals rather than mandatory significance tests for every event type.

Create a reproducible correction package

ICMJE statistical reporting recommendations emphasize methods detailed enough for informed readers with data to assess and verify results, and effect estimates with uncertainty rather than reliance on P values alone. A follow-up audit can apply that principle through the steps below. These are proposed activities, not completed reanalysis.

  1. Obtain the confirmed full report, protocol, data dictionary and authorized de-identified data, documenting access limitations.
  2. Check denominators, percentages, units and time windows table by table. Separate missing reporting, reproducible calculation errors and interpretation problems.
  3. Specify the primary endpoint and analysis population, including rules for missing follow-up, withdrawal, nonadherence and rescue treatment.
  4. Have statistical reviewers reproduce the planned analysis and justified alternatives, retaining code versions, reasons for changes and sensitivity results.
  5. Discuss any changes in conclusions jointly with gastroenterology and research teams. If reproduction is impossible, state the evidence gap.

Sample-size justification should prospectively address the primary outcome, clinically meaningful difference, significance level, power and anticipated attrition. An observed small P value cannot retrospectively establish adequate sample size. Illustrative eradication rates or hypothetical confidence intervals must never replace patient results.

QSevidence frequently asked questions

How can a QSevidence perspective organize the statistical audit?

Build a checklist covering document identity, intervention definition, outcome measurement and analysis. Link each question to its original location and criterion. Professional reviewers determine whether an error exists and interpret treatment effects using the available evidence and data.

How can a QSevidence perspective support bilingual evidence comparison?

Align terminology for eradication, healing, recurrence and adverse events while recording populations, denominators and assessment windows separately. Preserve the jurisdiction and design of each source so clinical researchers can judge transferability.

How can a QSevidence perspective help formulate corrections?

Group comments into additional reporting, data reanalysis and more restrained interpretation, with priorities and source locations. This supports communication without implying that the platform has verified a particular publication or established efficacy.

This article supports research-method learning, not individual eradication regimens, endoscopic procedures or medication-withdrawal decisions.